Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Emanuela Marina Bruscia · YALE UNIVERSITY · 2022 · $632,310 — PROJECT SUMMARY Macrophages (MΦs) kill microorganisms, engulf dead cells and debris, and regulate the immune response. They are thus gatekeepers of tissue health, including the lungs. The lung-tissue-resident MΦs (TR-MΦs) are the interstitial and alveolar MΦs, which have complementary but distinct f…
Lisa A Cavacini · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2022 · $694,299 — Project Summary The coronavirus disease 2019 (COVID-19) rapidly disseminated through the human population and became a global pandemic. Significant efforts have been put into developing vaccines or antibody therapies based on the spike glycoprotein of SARS-CoV-2. One challenge of such strategies is …
Michael-Christopher Keogh · EPICYPHER, INC. · 2022 · $1,020,317 — PROJECT SUMMARY Alterations in histone post-translational modifications (PTMs) are associated with diverse human pathologies. The ability to quantitatively assess these PTMs in healthy and diseased cells is essential to accelerate the development of drugs or diagnostics targeting epigenetic regulat…
Margaret Juliana McElrath · FRED HUTCHINSON CANCER RESEARCH CENTER · 2022 · $586,880 — Project Abstract This proposal outlines the scientific agenda for the COVID-19 Prevention Network (CoVPN) Vaccines Leadership Operations Center (LOC) for implementation of the COVID-19 vaccine efficacy trial entitled “A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficac…
Peter B. Gilbert · FRED HUTCHINSON CANCER CENTER · 2022 · $234,860 — Project Abstract This proposal outlines the scientific agenda for the COVID-19 Prevention Network (CoVPN) Vaccines Leadership Operations Center (LOC) for implementation of the COVID-19 vaccine efficacy trial entitled “A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the …
Mohammad Mohseni Sajadi · BALTIMORE VA MEDICAL CENTER · 2022 — Background/Rationale: As the Coronavirus Disease 2019 (COVID-19) epidemic expands across the United States and the world, there are no proven therapies and little information is known regarding on immunity to this virus. At this stage of the pandemic, all prevention and treatment strategies that sho…
Kenneth L Shepard · QUICKSILVER BIOSCIENCES, INC. · 2022 · $447,801 — Direct bioelectronic detection of SARS-CoV-2 from saliva using single-molecule field-effect transistor array Nucleic acid tests have become the gold-standard for diagnostic testing for COVID-19, usually performed in specialized laboratories. Most are based on reverse-transcription quantitative pol…
Samuel Matthew Young · UNIVERSITY OF IOWA · 2022 · $385,434 — The diversity of information encoding by neuronal circuits is regulated by the magnitude and location of Ca2+ entry though voltage-gated Ca2+ channels (CaV). In the mammalian central nervous system, the CaV2.1 channel is the critical subtype for CNS function since it is the most efficient CaV2 subty…
Radislav A Potyrailo · GENERAL ELECTRIC GLOBAL RESEARCH CTR · 2022 · $599,859 — PROJECT SUMMARY/ABSTRACT Available tools for detection of SARS-CoV-2 virus require extensive sample preparation and/or expensive lab- based equipment to obtain accurate results. The objective in this proposal is to build a touch-screen sensor array to directly capture, detect, and identify model SAR…
YAN XIANG · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · 2022 · $232,500 — Summary The novel coronavirus SARS-CoV-2 causes the COVID-19 pandemic. The virus infects through the respiratory tracts. While most COVID-19 patients display no or mild clinical symptoms, a small percentage develop severe immune-mediated pathological complications, which could lead to injury and fai…
Aleksandra Elzbieta Sikora · OREGON STATE UNIVERSITY · 2022 · $703,672 — ABSTRACT Neisseria gonorrhoeae (Ng), the gram-negative bacterium responsible for the sexually transmitted infection gonorrhea, is categorized as a high-priority pathogen for research and development efforts. In the US, over 50% of Ng isolates are resistant to at least one antimicrobial and the CDC h…
Anne Moscona · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2022 · $722,958 — No vaccines or treatments for SARS-CoV-2 are yet available. A simple prophylactic antiviral strategy would protect naïve individuals from infection now. In the future, when vaccines should be available, a prophylactic antiviral will be essential for individuals who do not mount a suitable immune res…
Deyu Fang · NORTHWESTERN UNIVERSITY AT CHICAGO · 2022 · $779,400 — Abstract Biomarker-guided treatment is key to improve outcomes of many diseases. The current COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a global crisis due to lagged vaccination and inefficient control of the virus, which has caused over 253 million c…
Elke BergmannLeitner · THOMAS JEFFERSON UNIVERSITY · 2022 · $225,781 — PROJECT SUMMARY As COVID-19 pandemic continues with the evolution of new strains, we acknowledge the groundwork that has been done evaluating maternal immunity following COVID-19 vaccine or disease exposure in pregnancy, and passive transmission of antibodies in cord blood and breastmilk. There rema…
Priyamvada Acharya · DUKE UNIVERSITY · 2022 · $695,359 — Structural characterization of Fab-dimerized glycan-reactive antibodies that neutralize HIV-1 A glycan shield covers the HIV-1 envelope (Env) limiting antibody access to broadly neutralizing antibody (bnAb) epitopes. 2G12 had for long been the only example of a HIV-1 bnAb that interacts solely with…
VINEET D MENACHERY · UNIVERSITY OF TEXAS MED BR GALVESTON · 2022 · $497,886 — Abstract The coronavirus (CoV) spike protein is a key viral determinant responsible for receptor binding and fusion/entry. The spike protein has also been predicted to be the major factor driving cross-species transmission, allowing the emergence of epidemic strains like SARS- and MERS-CoV. In the f…
Alex Joseph Guseman · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2022 · $100,000 — Project Summary/Abstract In late 2019, the SARS-CoV2 virus emerged as a global pandemic, causing the severe respiratory disease COVID-19 and resulting in millions of deaths worldwide. As a coronavirus, SARS-CoV2 host interactions are dictated through the Spike proteins that encompass the virion. The…
Kartik Balachandran · UNIVERSITY OF ARKANSAS AT FAYETTEVILLE · 2022 · $436,642 — PROJECT SUMMARY Recent reports have uncovered the role of angiotensin-converting enzyme 2 (ACE2) as the receptor for mediating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry into host cells. The aortic valve is one specific tissue within the cardiovascular system that has robust …
YUPING WANG · LOUISIANA STATE UNIV HSC SHREVEPORT · 2022 · $182,500 — COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged as the greatest threat to global health and significantly impact pregnant women worldwide. COVID-19 infection during pregnancy is associated with substantial risk of increases in maternal morbidity and mort…
Lanying Du · GEORGIA STATE UNIVERSITY · 2022 · $759,731 — Summary A novel coronavirus (CoV), SARS-CoV-2, is causing global pandemics with growing numbers of daily cases and deaths. SARS-CoV-2 is closely related to SARS-CoV, which caused the 2002-2003 SARS epidemic, and less closely related to MERS-CoV, which causes a high mortality rate in infected patient…